BMED Stock Analysis: Banca Mediolanum | MI

Banks - Regional | MI, Italy | Market Cap: 17.218m EUR | 12M Return: 28% | IT0004776628 | Charts, Fundamentals & Technical Analysis

Banking Accounts, Mortgage Lending, Asset Management, Insurance Policies
Total Rating 48
Safety 50
Buy Signal -0.10
Diversified Financial Services
Sub-Industry Rotation: -2.4
Market Cap: 18.9B
Avg Turnover: 17.8M
Risk 3d forecast
Volatility25.0%
VaR 5th Pctl4.45%
VaR vs Median8.21%
Reward TTM
Sharpe Ratio0.99
Rel. Str. IBD79
Rel. Str. Peer Group22.7 pctl
Character TTM
Beta0.591
Beta Downside0.095
Hurst Exponent0.460
Choppyness59.5%
Drawdowns 3y
Max DD21.11%
CAGR/Max DD2.33
CAGR/Mean DD16.14
EPS (Earnings per Share) EPS (Earnings per Share) of BMED over the last years for every Quarter: "2021-09": 0.15, "2021-12": 0.48, "2022-03": 0.153, "2022-06": 0.45, "2022-09": 0.19, "2022-12": 0.18, "2023-03": 0.24, "2023-06": 0.25, "2023-09": 0.29, "2023-12": 0.34, "2024-03": 0.3, "2024-06": 0.31, "2024-09": 0.3, "2024-12": 0.6, "2025-03": 0.33, "2025-06": 0.32, "2025-09": 0.34, "2025-12": 0.58, "2026-03": null, "2026-06": 0.377,
EPS CAGR: 25.13%
EPS Trend: 94.4%
Last SUE: 0.58
Qual. Beats: 0
Revenue Revenue of BMED over the last years for every Quarter: 2021-09: 324.01, 2021-12: 4723.785, 2022-03: 337.268, 2022-06: 346.537, 2022-09: 359.541, 2022-12: 492.469, 2023-03: 493.037, 2023-06: 572.217, 2023-09: 622.863, 2023-12: 735.418, 2024-03: 674.837, 2024-06: 689.434, 2024-09: 660.152, 2024-12: 991.338, 2025-03: 679.613, 2025-06: 653.653, 2025-09: 615.394, 2025-12: 1737.945, 2026-03: 881.8, 2026-06: 887.5,
Rev. CAGR: 22.16%
Rev. Trend: 95.3%
Last SUE: 0.15
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.9 years of data, until 10/2026

Jan +0.9% 0
Feb +0.2% 0
Mar +1.1% 0
Apr +1.0% 14
May +2.3% 28
Jun -2.5% 14
Jul +0.8% 4
Aug -1.8% 47
Sep -2.3% 14
Oct -0.2% 0
Nov +5.4% 9
Dec -0.2% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: BMED Banca Mediolanum

Banca Mediolanum S.p.A. is an Italian financial services company headquartered in Basiglio, founded in 1982. It provides a wide range of retail banking products, including current accounts, deposits, mortgage and personal loans, as well as credit, debit, and prepaid cards. Beyond traditional banking, the company offers investment products such as mutual funds, unit-linked policies, trading and asset management services, and bond issues, along with insurance coverage spanning life, health, serious illness, and family protection. It also distributes a set of branded assistance products under the SelfyCare line covering veterinary, travel, and life-project needs.

The company operates within Italys diversified financials sector and follows a bancassurance-style model, bundling banking, asset management, and insurance distribution through a single integrated platform aimed at household customers. It is listed on the Milan Stock Exchange under the ticker BMED and is classified as a large-cap stock within the GICS Diversified Financial Services sub-industry.

Headlines to Watch Out For
  • ECB rate cuts pressure net interest margin
  • Managed assets growth drives fee income expansion
  • Financial advisor network productivity underpins client acquisition
Piotroski VR-10 (Strict) 4.5
Net Income: 1.32b TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.82 > 1.0
NWC/Revenue: -97.74% < 20% (prev -1.63k%; Δ 1.53k% < -1%)
CFO/TA 0.05 > 3% & CFO 5.10b > Net Income 1.32b
Net Debt (5.00b) to EBITDA (1.57b): 3.17 < 3
Current Ratio: 0.12 > 1.5 & < 3
Outstanding Shares: last quarter (745.5m) vs 12m ago -0.13% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 4.45% > 50% (prev 3.47%; Δ 0.98% > 0%)
Interest Coverage Ratio: 4.21 > 6 (EBIT TTM 1.55b / Interest Expense TTM 368.9m)
Altman Z'' -0.08
A: -0.04 (Total Current Assets 555.8m - Total Current Liabilities 4.59b) / Total Assets 99.1b
B: 0.01 (Retained Earnings 555.5m / Total Assets 99.1b)
C: 0.02 (EBIT TTM 1.55b / Avg Total Assets 92.6b)
D: 0.05 (Book Value of Equity 4.58b / Total Liabilities 94.5b)
Altman-Z'' = -0.08 = B
Beneish M -2.87
DSRI: 1.02 (Receivables 719.0m/511.5m, Revenue 4.12b/2.98b)
GMI: 0.85 (GM 82.06% / 96.06%)
AQI: 1.00 (AQ_t 0.99 / AQ_t-1 0.99)
SGI: 1.38 (Revenue 4.12b / 2.98b)
TATA: -0.04 (NI 1.32b - CFO 5.10b) / TA 99.1b)
Beneish M = -2.87 (Cap -4..+1) = A
What is the price of BMED shares?

As of November 20, 2026, the stock is trading at EUR 22.25 with a total of 708,077 shares traded. Over the past week, the price has changed by -4.63%, over one month by -1.24%, over three months by -7.45% and over the past year by +28.02%.

Current recommended Stop Loss: 21.40 (which is 3.8% or 1.5 ATR below the current price).

Is BMED a buy, sell or hold?

Banca Mediolanum has no consensus analysts rating.

Banca Mediolanum (BMED) - Fundamental Data Overview as of 13 November 2026
Market Cap USD = 18.9b (17.2b EUR * 1.09717 EUR.USD)
P/E Trailing = 13.1299
P/E Forward = 11.1111
P/S = 6.7051
P/B = 3.888
P/EG = 0.2308
Revenue TTM = 4.12b EUR
EBIT TTM = 1.55b EUR
EBITDA TTM = 1.57b EUR
Long Term Debt = 647.1m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 4.59b EUR (from shortTermDebt, last quarter)
Debt = 5.19b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.00b EUR (calculated: Debt 5.19b - CCE 187.0m)
Enterprise Value = 22.2b EUR (17.2b + Debt 5.19b - CCE 187.0m)
Interest Coverage Ratio = 4.21 (Ebit TTM 1.55b / Interest Expense TTM 368.9m)
EV/FCF = 4.36x (Enterprise Value 22.2b / FCF TTM 5.10b)
FCF Yield = 22.93% (FCF TTM 5.10b / Enterprise Value 22.2b)
 FCF Margin = 123.6% (FCF TTM 5.10b / Revenue TTM 4.12b)
 Net Margin = 31.93% (Net Income TTM 1.32b / Revenue TTM 4.12b)
 Gross Margin = unknown ((Revenue TTM 4.12b - Cost of Revenue TTM 162.3m) / Revenue TTM)
 Tobins Q-Ratio = 0.22 (Enterprise Value 22.2b / Total Assets 99.1b)
Interest Expense / Debt = 7.11% (Interest Expense 368.9m / Debt 5.19b)
Taxrate = 15.21% (236.0m / 1.55b)
NOPAT = 1.32b (EBIT 1.55b * (1 - 15.21%))
Current Ratio = 0.12 (Total Current Assets 555.8m / Total Current Liabilities 4.59b)
Debt / Equity = 1.13 (Debt 5.19b / totalStockholderEquity, last quarter 4.58b)
Debt / EBITDA = 3.17 (Net Debt 5.00b / EBITDA 1.57b)
Debt / FCF = 0.98 (Net Debt 5.00b / FCF TTM 5.10b)
Total Stockholder Equity = 4.57b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.42% (Net Income 1.32b / Total Assets 99.1b)
RoE = 28.80% (Net Income TTM 1.32b / Total Stockholder Equity 4.57b)
RoCE = 29.75% (EBIT 1.55b / Capital Employed (Equity 4.57b + L.T.Debt 647.1m))
RoIC = 1.33% (NOPAT 1.32b / Invested Capital 99.0b)
WACC = 7.26% (E(17.2b)/V(22.4b) * Re(7.63%) + D(5.19b)/V(22.4b) * Rd(7.11%) * (1-Tc(0.15)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -45.82 | Cagr: 0.03%
[DCF] Terminal Value 77.97% ; FCFF base≈3.51b ; Y1≈4.03b ; Y5≈5.92b
[DCF] Fair Price = 113.6 (EV 89.2b - Net Debt 5.00b = Equity 84.2b / Shares 740.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.44 | EPS CAGR: 25.13% | SUE: 0.58 | # QB: 0
Revenue Correlation: 95.30 | Revenue CAGR: 22.16% | SUE: 0.15 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.37 | Chg30d=-0.56% | Revisions=-25% | Analysts=1
EPS next Quarter (2027-03-31): EPS=0.43 | Chg30d=+2.38% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.60 | Chg30d=+3.03% | Revisions=-38% | GrowthEPS=+2.4% | GrowthRev=-27.6%
EPS next Year (2027-12-31): EPS=1.61 | Chg30d=+2.05% | Revisions=+38% | GrowthEPS=+0.7% | GrowthRev=+0.7%
[Analyst] Revisions Ratio: +0% (up=6, down=6)